Drug or technology

Trastuzumab

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · PHASE 1 TRIAL

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

ClinicalTrials.gov

This is a Phase 1, first-in-human study registration with no results posted; it describes planned enrollment and safety endpoints only, representing early-stage drug development.

PreliminaryRibociclib Advanced Breast Cancer Metastatic Breast Cancer

Reported

Planned enrollment392

Study phasePhase 1

Primary endpoint 1Determination of maximum tolerated dose (MT…

AUG 12, 2026 · PHASE 3 TRIAL

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

ClinicalTrials.gov

This is a clinical trial registry record describing a completed Phase 3 study design with planned enrollment of 305 participants; no results are reported in this registry entry, only the study structure and primary outcome measure.

PreliminaryLaboratory Biomarker Analysis NCT00770809 National Cancer Institute (NCI)

Reported

Planned enrollment305

PhasePHASE3

Primary outcome measurepCR Rate at time of surgery

AUG 11, 2026 · PHASE 3 TRIAL

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

ClinicalTrials.gov

Phase 3 trial in active recruitment with no results posted; this registry record describes a planned study design and endpoints only, not outcomes.

PreliminaryTrastuzumab deruxtecan Trastuzumab Breast Neoplasms

Reported

Planned sample size927

Primary outcome measureRate of Pathologic Complete Response (pCR)

PhasePhase 3